NCT04854551View on ClinicalTrials.gov

Opioid Modulation and Neural Reward Activation in Healthy Adults

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

13

Participants

Timeline

Start Date

May 1, 2021

Primary Completion Date

April 18, 2022

Study Completion Date

April 18, 2022

Conditions
Alcohol DrinkingOpioid Use, Unspecified
Interventions
DRUG

Naltrexone

Naltrexone is an opioid antagonist with primary action at the mu opioid receptor.

OTHER

Placebo

Placebo will be used to control for expectancy effects

Trial Locations (1)

80045

University of Colorado Anschutz Medical Campus, Aurora

All Listed Sponsors
lead

University of Colorado, Denver

OTHER